Original news and analysis on international IP policy
The annual World Health Assembly kicks off next week with a full agenda of new and old public health issues, including several related to intellectual property, pricing, and research and development. Below is a guide to the key issues for Intellectual Property Watch readers.
The Geneva IP delegates list is updated! As a special feature for our subscribers, Intellectual Property Watch has assembled a new list of many of the leading government delegates working on intellectual property issues in Geneva.
BASEL -- Students from around the world are gathering momentum to challenge their universities’ licensing policies and research and development systems. That was one of the messages emerging from the annual meeting of Universities Allied for Essential Medicines (UAEM) Europe.
As the future United Nations development goals are being debated and decided, two important reports make the case for inclusion of a discussion on global governance and its impact on health.
The potential for big data to yield better outcomes in all aspects of health is tremendous, and tapping into it has only just begun, said speakers at a recent panel in Geneva.
Greg Perry has been executive director of the Medicines Patent Pool (MPP) for over a year now, since January 2013. Under his guidance, MPP shares that it has launched a “series of new licensing agreements and negotiations with key patent holders and generic medicines companies.” Intellectual Property Watch sat down with Perry recently to discuss why the MPP is so important as an alternative business model, the context of the MPP, changes in the global approach to the issue of access, and how the MPP fits within the Geneva context.
Non-communicable diseases, access and affordability, global health governance and information and communications technology innovation are some of the important issues discussed and debated at the recent Geneva Health Forum (GHF).
The Geneva Health Forum (GHF), taking place on 15-17 April in Geneva, will discuss the theme “Global Health: Interconnected Challenges, Integrated Solutions.” This year’s forum aims to encourage an “integrative approach” to global health, “which better captures the underlying causes of ill-health and recognises the commonalities that underlie people’s health around the world,” says GHF.
Guidelines for the treatment of hepatitis C released by the World Health Organization today recommend revolutionary new drugs for the virus. However, the exorbitant price of these drugs means they will remain out of reach for most of the millions infected. The WHO guidelines themselves offer limited recommendation for reducing prices, but may help in creating the conditions for price reduction by accruing demand and giving countries official backing in price negotiations.
The Global Fund to Fight AIDS, Tuberculosis and Malaria has launched an initiative with other agencies aimed at expanding global access to health products such as medicines. But the Fund has had some explaining to do about the initiative, which some say could encompass a plan to allow different prices based on national income levels.
The Medicines Patent Pool (MPP) this week announced two new licencing agreements with the private sector joint venture ViiV Healthcare that will increase access to a new antiretroviral in countries hardest hit by HIV.
UNITAID has published the full version of its report on “The Trans-Pacific Partnership Agreement: Implications for Access to Medicines and Public Health.”